Resverlogix Corp

(RVXCF)

By |

Profile

Resverlogix Corp is a clinical stage biotechnology company. It is engaged in developing RVX-208, a molecule selective inhibit BET domain inhibitor for the treatment of patients with cardiovascular, diabetes mellitus, Alzheimer's & chronic kidney disease.

Contact Information

Website: www.resverlogix.com
Email: sarah@resverlogix.com
Main Phone: +1 403 254-9252
Address: 4820 Richard Road SW
Address 2: Suite 300
State: AB
City / Town: Calgary
Country: CAN
Postal Code: T3E 6L1

Issuer Information

Exchange: OTO
CEO: Donald McCaffrey
Employees: 30
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)
$ 2.50 $ -0.08 (-3.10%)
Last Price 2.50 Change $ -0.08 Change % -3.10 Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open 2.41 High 2.56 Low 2.41 Prev Close 2.58
Last Trade Volume 17,850 52 Wk Hi 3.45 52 Wk Low 0.84
Market Cap 471.3 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 188,527,216.00 EPS (TTM) N/A PE Ratio N/A Exchange OTCPK